Trials / Conditions / Neurofibromatosis Type 2

Neurofibromatosis Type 2

16 registered clinical trials studyying Neurofibromatosis Type 2.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Doxycycline in Cutaneous Schwannoma (NF2) NCT05521048	Massachusetts Eye and Ear Infirmary	Phase 1 / Phase 2
Terminated	Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningioma NCT05130866	Recursion Pharmaceuticals Inc.	Phase 2 / Phase 3
Active Not Recruiting	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF NCT04374305	Scott R. Plotkin, MD, PhD	Phase 2
Completed	WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data NCT03210285	University Hospital Tuebingen	—
Completed	Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors NCT02934256	Li Peng	Phase 2
Terminated	Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Me NCT02282917	Massachusetts Eye and Ear Infirmary	EARLY_Phase 1
Terminated	Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma NCT01345136	Jonsson Comprehensive Cancer Center	Phase 2
Completed	Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas NCT02129647	NYU Langone Health	Phase 2
Completed	Effect of Implant Position on Magnetic Resonance Image Distortion NCT02246231	Manchester University NHS Foundation Trust	N/A
Completed	Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors NCT02104323	Beijing Tiantan Hospital	Phase 2
Completed	Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas NCT01880749	NYU Langone Health	EARLY_Phase 1
Completed	Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas NCT01767792	University of Alabama at Birmingham	Phase 2
Active Not Recruiting	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434	M.D. Anderson Cancer Center	Phase 1
Completed	Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) NCT01207687	National Cancer Institute (NCI)	Phase 2
Completed	Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas NCT01125046	Northwestern University	Phase 2
No Longer Available	Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients NCT02589912	Massachusetts Eye and Ear Infirmary	—